News >

Lapatinib/Trastuzumab/AI Triplet Nearly Doubles PFS in HER2+/HR+ Metastatic Breast Cancer

Jason Harris
Published: Friday, Jul 07, 2017

William J. Gradishar MD

William J. Gradishar MD

The triplet combination of HER2-targeted therapy and an aromatase inhibitor (AI) improved progression-free survival (PFS) by more than 5 months compared with the combination of trastuzumab (Herceptin) and an AI in patients with HER2+/HR+ breast cancer.

In the lapatinib/trastuzumab/AI group, 34% of patients experienced grade 3/4 AEs, primarily diarrhea (13%). In the lapatinib/AI group, 32% of patients experienced grade 3/4 AEs, and, again, diarrhea was the most common (6%). Twenty-two percent of patients in the trastuzumab/AI group experienced serious AEs, with ALT and AST increases being the most common (4% each).
Gardishar WJ, Hegg R, Im S, et al. Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. J Clin Oncol 35, 2017 (suppl; abstr 1004).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication